---
title: "Arvinas, Inc. (ARVN.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/ARVN.US.md"
symbol: "ARVN.US"
name: "Arvinas, Inc."
industry: "Pharmaceuticals"
datetime: "2026-05-20T12:40:58.100Z"
locales:
  - [en](https://longbridge.com/en/quote/ARVN.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/ARVN.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/ARVN.US.md)
---

# Arvinas, Inc. (ARVN.US)

## Company Overview

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins. It is also developing clinical development programs , including ARV-102, a leucine-rich repeat kinase 2 (LRRK2) protein for the treatment of neurodegenerative diseases, such as Parkinson's disease and progressive supranuclear palsy; ARV-806, a Kirsten rat sarcoma, G12D protein for the treatment of cancers with the G12D mutation, comprising pancreatic, colorectal, and non-small cell lung cancer; ARV-393, a B-cell lymphoma 6 protein for the treatment of relapsed/refractory non-Hodgkin lymphoma (NHL); ARV-027, a polyglutamine-expanded androgen receptor in skeletal muscle; and vepdegestrant, an estrogen receptor for the treatment of locally advanced or metastatic ER+/HER2- breast cancer. In addition, the company develops Bavdegalutamide (ARV-110) and Luxdegalutamide (ARV-766), investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | US Market |
| Website | [www.arvinas.com](https://www.arvinas.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:16.000Z

**Overall: D (0.76)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 137 / 189 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -79.06% |  |
| Net Profit YoY | -374.89% |  |
| P/B Ratio | 1.43 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 551656242.90 |  |
| Revenue | 89400000.00 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -42.28% | E |
| Profit Margin | -247.54% | E |
| Gross Margin | -284.62% | E |
| Revenue YoY | -79.06% | E |
| Net Profit YoY | -374.89% | E |
| Total Assets YoY | -35.32% | E |
| Net Assets YoY | -41.40% | E |
| Cash Flow Margin | 114.82% | C |
| OCF YoY | -79.06% | E |
| Turnover | 0.11 | E |
| Gearing Ratio | 40.26% | C |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Arvinas, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-79.06%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-374.89%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "1.43",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "551656242.90",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "89400000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-42.28%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-247.54%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "-284.62%",
          "rating": "E"
        },
        {
          "name": "Revenue YoY",
          "value": "-79.06%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "-374.89%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "-35.32%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-41.40%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "114.82%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "-79.06%",
          "rating": "E"
        },
        {
          "name": "Turnover",
          "value": "0.11",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "40.26%",
          "rating": "C"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -2.49 | 141/189 | - | - | - |
| PB | 1.43 | 73/189 | 1.52 | 1.28 | 0.86 |
| PS (TTM) | 6.17 | 105/189 | 2.65 | 2.31 | 1.35 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Cormedix (CRMD.US) | A | A | B | C | B | A |
| 02 | Eli Lilly (LLY.US) | A | A | B | D | B | B |
| 03 | ROCHE HOLDINGS AG (RHHVF.US) | A | B | B | D | B | B |
| 04 | Roche (RHHBY.US) | A | B | B | D | B | B |
| 05 | AstraZeneca (AZN.US) | A | B | C | D | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-15T04:00:00.000Z

Total Analysts: **19**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 8 | 42% |
| Overweight | 2 | 11% |
| Hold | 8 | 42% |
| Sell | 1 | 5% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 8.55 |
| Highest Target | 21.00 |
| Lowest Target | 6.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/ARVN.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/ARVN.US/norm.md)
- [Related News](https://longbridge.com/en/quote/ARVN.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/ARVN.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**